Morgan Stanley Maintains Overweight on Immunocore Hldgs, Lowers Price Target to $74
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Andrew Galler maintains an Overweight rating on Immunocore Holdings (NASDAQ:IMCR) but lowers the price target from $80 to $74.
October 11, 2024 | 4:31 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained its Overweight rating on Immunocore Holdings but has lowered the price target from $80 to $74, indicating a slightly less optimistic outlook.
The maintenance of an Overweight rating suggests continued confidence in Immunocore Holdings, but the lowered price target from $80 to $74 indicates a tempered outlook, which could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100